CASC3 and AL amyloidosis: BTZ is a proteasome inhibitor that is the first-line treatment for multiple myeloma and mantle cell lymphoma, and BTZ-induced peripheral neuropathy (BIPN) is estimated to occur in 37-44% of patients (Grisold et al., 2012).